SAN DIEGO, Sept. 17, 2020 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that its
collaborator, Roche, presented a poster with data from Part 1 of
its Phase 1b study (IMscin001)
evaluating atezolizumab (Tecentriq®) for subcutaneous
administration utilizing Halozyme's ENHANZE® technology
in patients with locally advanced or metastatic non-small cell lung
cancer (NSCLC) at the ESMO Virtual Congress 2020.
The Phase 1b dose-finding study
enrolled 67 patients with advanced/metastatic NSCLC previously
treated with chemotherapy (no prior cancer immunotherapy) in 3
cohorts. The poster concluded that atezolizumab utilizing
ENHANZE® was well tolerated, provided similar exposure
as atezolizumab IV and that results support further development of
subcutaneous atezolizumab in IMscin001 Part 2, a confirmatory phase
III study.
"We are pleased that the results from Roche's Phase 1b evaluating atezolizumab with
ENHANZE® support continued development in a Phase 3
study," said Dr. Helen Torley,
president and chief executive officer.
The subcutaneous formulation of atezolizumab is being developed
to potentially allow faster administration via subcutaneous
injection under the skin, compared to the original intravenous (IV)
formulation, thereby significantly reducing a patient's time spent
receiving treatment.
About Halozyme
Halozyme is a biopharmaceutical company
bringing disruptive solutions to significantly improve patient
experiences and outcomes for emerging and established therapies.
Halozyme advises and supports its biopharmaceutical partners in key
aspects of new drug development with the goal of improving
patients' lives while helping its partners achieve global
commercial success. As the innovators of the ENHANZE®
technology, which can reduce hours-long treatments to a matter of
minutes, Halozyme's commercially-validated solution has positively
impacted more than 400,000 patient lives via five commercialized
products across more than 100 global markets. Halozyme and its
world-class partners are currently advancing multiple therapeutic
programs intended to deliver innovative therapies, with the
potential to improve the lives of patients around the globe.
Halozyme's proprietary enzyme rHuPH20 forms the basis of the
ENHANZE® technology and is used to facilitate the
delivery of injected drugs and fluids, potentially reducing the
treatment burden of other drugs to patients. Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme
derives revenues from these collaborations in the form of
milestones and royalties as the Company's partners make progress
developing and commercializing their products being developed with
ENHANZE®. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements including, without
limitation, the product development and approval efforts of
Halozyme's ENHANZE® partners, including the potential
continued evaluation of atezolizumab with ENHANZE® in a
Phase 3 clinical study, and statements concerning the possible
activity, benefits and attributes of ENHANZE®, the
possible method of action of ENHANZE®, its potential
application to aid in the dispersion and absorption of other
injected therapeutic drugs, and statements concerning certain other
potential benefits of ENHANZE® including facilitating
more rapid delivery of injectable medications through subcutaneous
delivery and lowering the treatment burden for patients. These
forward-looking statements also include statements. These
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including uncertainties concerning whether the
collaborative product referred to in this press release is
ultimately developed, approved or commercialized, unexpected
expenditures and costs, unexpected results or delays in development
and regulatory review including any potential delays caused by the
current COVID-19 global pandemic, unexpected regulatory approval
requirements, unexpected adverse events or patient outcomes and
competitive conditions. These and other factors that may result in
differences are discussed in greater detail in Halozyme's most
recent Annual and Quarterly Reports filed with the Securities and
Exchange Commission. Except as required by law, Halozyme undertakes
no duty to update forward-looking statements to reflect events
after the date of this release.
Tecentriq® (atezolizumab) is a registered trademark
of Genentech, a member of the Roche Group.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-poster-presentation-of-data-from-roches-phase-1b-study-evaluating-atezolizumab-for-subcutaneous-administration-utilizing-enhanze-in-non-small-cell-lung-cancer-301132876.html
SOURCE Halozyme Therapeutics, Inc.